Dynavax Technologies Corp (DVAX)

[eastunder]

Dynavax Technologies Receives European Marketing Approval for Hepatitis B Vaccine; Shares Rise Midday
1:08 PM ET, 02/19/2021 - MT Newswires

01:08 PM EST, 02/19/2021 (MT Newswires) -- Dynavax Technologies (DVAX) said the European Commission has granted marketing authorization for Heplisav-B, the biopharmaceutical company's vaccine for hepatitis B in adults 18 and older.

The approval follows a positive opinion from the European Medicines Agency on Dynavax's marketing authorization application, which was based on safety and immunogenicity results from three phase 3 clinical trials. European Commission marketing authorization approval is valid in all EU countries and Norway, Iceland, and Liechtenstein.

Shares of Dynavax are up more than 5% in midday trading.